España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
CureVac
CVAC
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$3.96
-0.18
-4.35%
At close: -
$3.90
-0.06
-1.52%
After Hours: 5:00 PM EDT
Get Report
Comment
CureVac (CVAC) Forecast
News
Earnings
CureVac (CVAC) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for CureVac (NASDAQ:CVAC) Stock
CureVac Stock (NASDAQ: CVAC)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Tuesday, January 21, 2025
Bird Flu Update: First Commercial Case In Georgia, Moderna Receives $590 Million To Develop Vaccine
Erica Kollmann
Thursday, January 16, 2025
Bird Flu Raising Red Flags Among Health Officials, CDC Urges Faster Testing
Erica Kollmann
Friday, January 10, 2025
Why CureVac (CVAC) Shares Are Volatile
Henry Khederian
Wednesday, January 08, 2025
Why CureVac (CVAC) Stock Is Moving
Henry Khederian
Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies
Chandrima Sanyal
Tuesday, January 07, 2025
US Records First Human Bird Flu Death, High Levels Of Respiratory Illnesses: Vaccine Stocks Rally
Erica Kollmann
Shares of vaccine makers are trading higher a...
Benzinga Newsdesk
Shares of vaccine makers are trading higher a...
Benzinga Newsdesk
Monday, January 06, 2025
Why CureVac (CVAC) Stock Is Rising
Henry Khederian
Tuesday, November 12, 2024
CureVac Reaffirms Its Expected Cash Runway In...
Benzinga Newsdesk
CureVac Q3 Sales EUR493.90M Beat EUR103.76M E...
Benzinga Newsdesk
Earnings Scheduled For November 12, 2024
Benzinga Insights
Monday, November 11, 2024
Insights into CureVac's Upcoming Earnings
Benzinga Insights
Monday, November 04, 2024
CureVac Named Axel Sven Malkomes as CFO
Benzinga Newsdesk
Tuesday, October 08, 2024
Reuters Reported Pfizer, Biontech Win Bid In ...
Benzinga Newsdesk
Monday, September 16, 2024
JMP Securities Reiterates Market Outperform o...
Benzinga Newsdesk
Friday, September 13, 2024
CureVac shares are trading higher after the c...
Benzinga Newsdesk
CureVac's CVGBM Cancer Vaccine Induces Immune...
Benzinga Newsdesk
Thursday, September 12, 2024
GSK Reveals 'Positive' Data From Mid-Stage Study Of Seasonal Influenza mRNA Vaccine
Vandana Singh
Earlier Today, GSK Announced Headline Results...
Benzinga Newsdesk
Friday, August 16, 2024
JMP Securities Maintains Market Outperform on...
Benzinga Newsdesk
Thursday, August 15, 2024
CureVac Q2 Sales €14.400M May Not Be Comparab...
Benzinga Newsdesk
CureVac Advances Cancer Vaccine Candidate CVG...
Benzinga Newsdesk
Thursday, July 11, 2024
CureVac Announced The Latest Trial Dates For ...
Benzinga Newsdesk
Wednesday, July 03, 2024
JMP Securities Reiterates Market Outperform o...
Benzinga Newsdesk
GSK Buys Full Rights To Investigational Covid-19 And Influenza Vaccines From CureVac For Around $1.5B
Vandana Singh
CureVac shares are trading higher after the c...
Benzinga Newsdesk
CureVac Secures €400M Upfront and Up to €1.05...
Benzinga Newsdesk
CureVac Restructures to Focus on High-Value m...
Benzinga Newsdesk
GSK and CureVac Restructure Partnership, Focu...
Benzinga Newsdesk
Tuesday, June 18, 2024
Why Quantum Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Avi Kapoor
Thursday, June 06, 2024
First Human Death From Bird Flu Strain Puts Vaccine Stocks Back On The Map
Natan Ponieman
Wednesday, June 05, 2024
'First-ever human death of bird flu strain H5...
Benzinga Newsdesk
Why Lands' End Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Avi Kapoor
Ollie's Bargain Outlet Posts Upbeat Earnings, Joins Verint Systems, Guidewire Software And Other Big Stocks Moving Higher On Wednesday
Avi Kapoor
Tuesday, May 28, 2024
CureVac Has Dosed The First Participant In Ph...
Benzinga Newsdesk
Thursday, May 23, 2024
CureVac's Cash And Cash Equivalents Position ...
Benzinga Newsdesk
CureVac Reported Q1 2024 Pre-Tax Loss Of €69....
Benzinga Newsdesk
CureVac Q1 2024 Sales €12.400M Beat €12.030M ...
Benzinga Newsdesk
Wednesday, May 22, 2024
Why XP Shares Are Trading Lower By Around 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Avi Kapoor
Analog Devices Posts Strong Earnings, Joins TJX, Williams-Sonoma And Other Big Stocks Moving Higher On Wednesday
Avi Kapoor
Friday, May 17, 2024
Despegar.com Posts Strong Sales, Joins Reddit, Robinhood And Other Big Stocks Moving Higher On Friday
Avi Kapoor
Thursday, May 09, 2024
Elon Musk Breaks Ranks With GOP By Praising Genetic Engineering Tech That Helped Fight COVID-19: 'Digital Medicine With Incredible Potential'
Shanthi Rexaline
Monday, May 06, 2024
Spirit Airlines Posts Weak Results, Joins Integra LifeSciences, Bowlero And Other Big Stocks Moving Lower On Monday
Avi Kapoor
Friday, April 26, 2024
COVID-19 Patent Dispute Sorted: Acuitas Therapeutics and CureVac Reach Settlement In Patent Battle
Vandana Singh
Thursday, April 25, 2024
CureVac shares are trading lower after Leerin...
Benzinga Newsdesk
Leerink Partners Downgrades CureVac to Market...
Benzinga Newsdesk
Wednesday, April 24, 2024
CureVac shares are trading lower after the co...
Benzinga Newsdesk
CureVac Has Started The Phase 1 Part Of A Com...
Benzinga Newsdesk
CureVac And GSK Will End The Pandemic Prepare...
Benzinga Newsdesk
Show More